Search Results - Takafumi Kubo

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men

    Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men by Hirokazu Taniguchi, Kumpei Tanisawa, Xiaomin Sun, Takafumi Kubo, Mitsuru Higuchi

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Effects of short‐term endurance exercise on gut microbiota in elderly men

    Effects of short‐term endurance exercise on gut microbiota in elderly men by Hirokazu Taniguchi, Kumpei Tanisawa, Xiaomin Sun, Takafumi Kubo, Yuri Hoshino, Masahito Hosokawa, Haruko Takeyama, Mitsuru Higuchi

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma

    Epigenetic Silencing of MicroRNA-34b/c Plays an Important Role in the Pathogenesis of Malignant Pleural Mesothelioma by Takafumi Kubo, Shinichi Toyooka, Kazunori Tsukuda, Masakiyo Sakaguchi, Takuya Fukazawa, Junichi Soh, Hiroaki Asano, Tsuyoshi Ueno, Takayuki Muraoka, Hiromasa Yamamoto, Yasutomo Nasu, Takumi Kishimoto, Harvey I. Pass, Hideki Matsui, Nam‐ho Huh, Shinichiro Miyoshi

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial

    LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial by Keiko Goto, K. Sang-We, Takafumi Kubo, Y. Goto, M-J. Ahn, David Planchard, Dong‐Wook Kim, J.C.-H. Yang, T-Y. Yang, Kaline Pereira, Kapil Saxena, Ryota Shiga, Yun Cheng, Mehreteab Aregay, Pasi A. Jänne

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    <i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

    <i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors by Takafumi Kubo, Hiromasa Yamamoto, William W. Lockwood, Ilse Valencia, Junichi Soh, Michael Peyton, Masaru Jida, Hiroki Otani, Tetsuya Fujii, Mamoru Ouchida, Nagio Takigawa, Katsuyuki Kiura, Kenji Shimizu, Hiroshi Date, John D. Minna, Marileila Varella‐Garcia, Wan L. Lam, Adi F. Gazdar, Shinichi Toyooka

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: